Cover Image
Read Now

Systematic reviews on selected pharmacogenetic tests for cancer treatment CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia

The challenges in the integration of cancer pharmacogenetics and targeted therapies in clinical practice should require evidence of benefit to the patients (a favorable balance of harms and benefits of testing), cost-effectiveness for the healthcare system, incorporating patient preferences, improvi...

Full description

Bibliographic Details
Main Authors: Terasawa, Teruhiko, Dahabreh, Issa J. (Author), Castaldi, Peter J. (Author), Trikalinos, Thomas A. (Author)
Corporate Authors: Technology Assessment Program (Agency for Healthcare Research and Quality), Tufts Evidence-based Practice Center
Format: eBook
Language:English
Published: Rockville, Maryland AHRQ Technology Assessment Program June 7, 2010, 2010
Series:Technology assessment report
Subjects:
Leukemia, Myelogenous, Chronic, Bcr-abl Positive / Drug Therapy
Colorectal Neoplasms / Drug Therapy
Breast Neoplasms / Drug Therapy
Pharmacogenetics / Methods
Antineoplastic Agents / Pharmacokinetics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Table of Contents:
  • Includes bibliographical references

Similar Items